surgery, antibiotic therapy and other supportive measures. Review is not mandated for this indication however the following criteria may be useful in assessing the effectiveness of therapy. Outcome data to be measured One survival Documented clinical response to Ig therapy. Dose Induction dose - 2 g/kg as a single dose. Dosing unchanged - minor revision to script. 2 g/kg as a single dose. Schrage et al (2006) reported differences There have been reported differences between between various preparations of IVIg and their various preparations of IVIg and their ability to ability to neutralise streptococcal neutralise streptococcal superantigens that may superantigens. They commented that relate to geographical regions from which the ‘the variations between IVIg preparations from plasma was collected, which may reflect different manufacturers are most likely caused differences in Group A streptococcal exposure by the different geographical regions from (Schrage et al 2006). The clinical significance of which the plasma samples were collected and these findings is not yet known. might reflect differences in ... group A streptococcal ... exposure.’ The clinical Darenburg et al (2004) suggested that higher significance of these findings is not yet known. doses of IVIg might be required for
surgery, antibiotic therapy and other supportive measures. Review is not mandated for this indication however the following criteria may be useful in assessing the effectiveness of therapy. Outcome data to be measured One survival Documented clinical response to Ig therapy. Dose 2 g/kg as a single dose. Schrage et al (2006) reported differences between various preparations of IVIg and their ability to neutralise streptococcal superantigens. They commented that ‘the variations between IVIg preparations from different manufacturers are most likely caused by the different geographical regions from which the plasma samples were collected and might reflect differences in ... group A streptococcal ... exposure.’ The clinical significance of these findings is not yet known. Induction dose - 2 g/kg as a single dose. There have been reported differences between various preparations of IVIg and their ability to neutralise streptococcal superantigens that may relate to geographical regions from which the plasma was collected, which may reflect differences in Group A streptococcal exposure (Schrage et al 2006). The clinical significance of these findings is not yet known. Darenburg et al (2004) suggested that higher doses of IVIg might be required for Dosing unchanged - minor revision to script.